Table 2.
Study | Design | Patient | n | Age (years) | Paracetamol dose | Duration | Baseline systolic BP (mmHg) | End systolic BP (mmHg) | Change in systolic BP (mmHg) |
---|---|---|---|---|---|---|---|---|---|
Chalmers et al. 40 | Randomized, double-blind, two phase, crossover, placebo- controlled | HTN OA | 22 | – | 1 g three times daily | 4 weeks | – | – | 4 |
Lewis et al. 41 | Unblinded, three phase, crossover | HTN OA | 21 | 62 | 1 g four times daily | 2 weeks | 110.3 (MAP) | 103.8 (MAP) | −6.5 (MAP) |
Radack et al. 42 | Randomized, double-blind, parallel groups, placebo controlled | HTN | 15 | 53 | 1 g four times daily | 3 weeks | 123 | – | 0.2 |
Chau et al. 43 | Randomized, double-blind, three phase, crossover | HTN | 12 | 31–71 | 650 mg | Once | – | 121 ± 12 | 1.2 ± 6.0 |
Pavlicevic et al. 44 | Randomized, single-blind, three phase, parallel groups | HTN | 49 | 70 | 1 g three times daily | 1 month | 139.3L | 133.9L/I/Pa | −5.4 |
133.3L | 132.9L/P/Pa | −0.4 | |||||||
144.8A | 142.0A/I/Pa | −2.8 | |||||||
130.2A | 131.4A/P/Pa | 1.2 | |||||||
Sudano et al. 28 | Randomized, double-blind, two phase, crossover, placebo controlled | CAD | 33 | 61 | 1 g three times daily | 2 weeks | 122 | 125 | 3 |
A, amlodipine; CAD, coronary artery disease; HTN, hypertension; I, ibuprofen; L, lisinopril/hydrochlorothiazide; MAP, mean arterial pressure; OA, osteoarthritis; P, piroxicam; Pa, paracetamol.